Skip to content
Bored Studies
RecruitingPhase 2

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Deciphera Pharmaceuticals, LLC · NCT06619561

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
48
US sites recruiting
26
Study start
November 21, 2024
Record last updated
December 15, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.

Being studied: Vimseltinib

Conditions: Chronic Graft-Versus-Host Disease (cGVHD)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Must be allogeneic hematopoietic stem cell transplant (HSCT) recipients with moderate to severe cGVHD requiring systemic immune suppression.

a. May have persistent active acute GVHD (aGVHD) and chronic GVHD (cGVHD) manifestations (overlap syndrome).

  • Participants with active cGVHD who have received and failed at least 2 prior lines of systemic therapy.
  • Stable dose of systemic corticosteroids is permitted but not required. If being taken, participants should be on a stable dose of corticosteroids for at least 2 weeks prior to starting study drug treatment.
  • Adequate organ and bone marrow functions.
  • Participants of reproductive potential agree to follow the contraception requirements.
  • Karnofsky Performance Scale (KPS) of ≥60.

Exclusion Criteria

  • Has aGVHD without manifestations of cGVHD.
  • Prior use of colony-stimulating factor 1 receptor (CSF1R) inhibitor for cGVHD.
  • History or other evidence of severe illness, uncontrolled infection, or any other conditions that would make the participant unsuitable for the study. All wounds must be healed and free of infection or dehiscence.
  • History of malignancy except for:
  • Underlying malignancy for which the transplant was performed
  • Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to enrollment and felt to be at low risk for recurrence.
  • Malabsorption syndrome or other illness that could affect oral absorption.

Recruiting US locations

Study contacts (from the official record)

  • Clinical Team · 888-724-3274 · clinicaltrials@deciphera.com
A Study to Evaluate Vimseltinib in Adults With Active Chronic… (NCT06619561) | Bored Studies